Comorbidity in Severe Asthma Requiring Systemic Corticosteroid Therapy: Cross-sectional Data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
Overview
Authors
Affiliations
Objective: To determine the prevalence of systemic corticosteroid-induced morbidity in severe asthma.
Design: Cross-sectional observational study.
Setting: The primary care Optimum Patient Care Research Database and the British Thoracic Society Difficult Asthma Registry.
Participants: Optimum Patient Care Research Database (7195 subjects in three age- and gender-matched groups)-severe asthma (Global Initiative for Asthma (GINA) treatment step 5 with four or more prescriptions/year of oral corticosteroids, n=808), mild/moderate asthma (GINA treatment step 2/3, n=3975) and non-asthma controls (n=2412). 770 subjects with severe asthma from the British Thoracic Society Difficult Asthma Registry (442 receiving daily oral corticosteroids to maintain disease control).
Main Outcome Measures: Prevalence rates of morbidities associated with systemic steroid exposure were evaluated and reported separately for each group.
Results: 748/808 (93%) subjects with severe asthma had one or more condition linked to systemic corticosteroid exposure (mild/moderate asthma 3109/3975 (78%), non-asthma controls 1548/2412 (64%); p<0.001 for severe asthma versus non-asthma controls). Compared with mild/moderate asthma, morbidity rates for severe asthma were significantly higher for conditions associated with systemic steroid exposure (type II diabetes 10% vs 7%, OR=1.46 (95% CI 1.11 to 1.91), p<0.01; osteoporosis 16% vs 4%, OR=5.23, (95% CI 3.97 to 6.89), p<0.001; dyspeptic disorders (including gastric/duodenal ulceration) 65% vs 34%, OR=3.99, (95% CI 3.37 to 4.72), p<0.001; cataracts 9% vs 5%, OR=1.89, (95% CI 1.39 to 2.56), p<0.001). In the British Thoracic Society Difficult Asthma Registry similar prevalence rates were found, although, additionally, high rates of osteopenia (35%) and obstructive sleep apnoea (11%) were identified.
Conclusions: Oral corticosteroid-related adverse events are common in severe asthma. New treatments which reduce exposure to oral corticosteroids may reduce the prevalence of these conditions and this should be considered in cost-effectiveness analyses of these new treatments.
Natural killer cells in the lung: novel insight and future challenge in the airway diseases.
Pianigiani T, Paggi I, Cooper G, Staples K, McDonnell M, Bergantini L ERJ Open Res. 2025; 11(2).
PMID: 40071269 PMC: 11895099. DOI: 10.1183/23120541.00683-2024.
Health system characteristics and evidence-based asthma care.
Crawford A, Jones G, Scullion J, Ryan D, Blakey J Front Allergy. 2025; 6:1528526.
PMID: 40065833 PMC: 11891166. DOI: 10.3389/falgy.2025.1528526.
Diabetes-inducing effects of bronchial asthma.
Al-Beltagi M, Bediwy A, Saeed N, Bediwy H, Elbeltagi R World J Diabetes. 2025; 16(1):97954.
PMID: 39817208 PMC: 11718464. DOI: 10.4239/wjd.v16.i1.97954.
Heffler E, Blasi F, Paggiaro P, Canonica G Adv Ther. 2025; 42(2):1196-1206.
PMID: 39754702 PMC: 11787275. DOI: 10.1007/s12325-024-03071-w.
Maintenance oral steroids are not required in severe asthma.
Graham E, Eames C, Soe W, Fox L, Whitfield C, Kerley S ERJ Open Res. 2024; 10(6).
PMID: 39687394 PMC: 11647928. DOI: 10.1183/23120541.00568-2024.